Hepatic Metastases of Gastroenteropancreatic Neuroendocrine Tumors: A 17-Year Single Center Prospective Study

#822

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NET) with hepatic metastases (HM) have a poorer prognosis in comparison with localized GEP NET.

Aim(s): Primary endpoints of the study are overall survival from the diagnosis of liver metastases (OS), progression-free survival (PFS) and treatment effectiveness.

Materials and methods: Among 186 consecutive patients with diagnosed GEP NET from 1995 to 2012, 74 had HM. Prognostic factors and survival times of GEP NET with HM with different treatments were calculated using Kaplan-Meier method and regression analysis.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Rossi R

Authors: Spampatti M, Massironi S, Rossi R, Ciafardini C, Galeazzi M,

Keywords: neuroendocrine tumors, hepatic metastases,